Another study demonstrated that a lower NK/CD4+ T cell ratio in IFN-β-treated early RR-MS patients had prognostic value for disease activity compared to the CD56dim subset, while CD56bright NK cell count was negatively correlated with CD4+ T cell and more specifically, CD4+IL-17A+ T cell numbers (166). The gene discussed is CD4; the disease is myeloid sarcoma.